Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) and maintained a price target of $55.
October 30, 2024 | 9:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Rhythm Pharmaceuticals and maintained a price target of $55, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $55 price target by a reputable analyst suggests a positive outlook for Rhythm Pharmaceuticals. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100